UNMETNEEDFOREARLIERCANCER DETECTION Cancer is often detected at late-stage (Stages III and IV) after symptoms have appeared, resulting in a poor prognosis for patients. Earlier detection of cancer increases treatment options, improves patient outcomes and increases 5-year survival rates. Existing diagnostic tests can suffer from high falsepositives and/or insufficient sensitivity for early-stage cancer (stages 1 and II). Additionally, there is often poor screening participation due to existing tests being invasive, inconvenient, inaccessible, or expensive. There is a clear unmet need for non-invasive, accurate and reliable tests for earlier detection of cancer. 5-year survival rates by stage at diagnosis The Group is well positioned to develop and commercialise cancer diagnostic products for the screening, diagnosis, prognosis and monitoring of multiple cancers based on our proprietary technologies. EXOSOMESHAVEHUGEPOTENTIAL AS NOVEL BIOMARKERS FORMULTIPLE DISEASESANDAPPLICATIONS Exosomes are small extracellular vesicles (EVs) released by all cells. They are nanometre-sized lipid membrane packages that encapsulate (and protect from degradation) DNA, RNAs and proteins. EVs and the messages they carry form part of the cell-to-cell communicatione system and play an important role in health and disease. Intercepting and reading EVmessages has important applications in the research, diagnosis and treatment of many diseases, including: cancer, cardiometabolic, inflammatory, neurodegenerative and other diseases. Clinical interest in exosomes has grown exponentially due to their commercial potential in drug delivery, disease diagnosis and treatment of cancer. Advancements in exosome research have been limited by slow, impure and inefficient traditional methods to isolate exosomes. There is an unmet need for fast, precise and scalable isolation of exosomes for research and commercial applications. INOVIQ has developed a rapid and efficient way (EXO-NET) to isolate EVs from biofluids to intercept and decode the messages that they contain. This information can be used for assessing patient well-being or disease risk, diagnosis of disease, selecting the best treatment option, or monitoring a patient’s response to treatment. 6% 28% 6% 30% 3% 30% 77% 90% 21% 49% 10% 98% 96% 99% 59% 93% 39% 100% 0% 20% 40% 60% 80% 100% 120% Bladder Breast Lung Ovarian Pancreatic Prostate Late Average Early 9 Annual Report 2022
RkJQdWJsaXNoZXIy MjE2NDg3